Clinical Trial: Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07250269) titled 'Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis' on Oct. 21.

Brief Summary: This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.

Study Start Date: Oct. 29

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory AL Amyloidosis

Intervention: DRUG: GC012F Injection

The investigational agent, GC012F, is an autologous BCMA/CD19 dual directed CAR product under investigation for the treatment of patients with RRMM, ELMM, SLE, and B NHL....